APT-1011 Market Summary

Key Factors Driving APT-1011 Growth

1. Addressing a Significant Unmet Need in Eosinophilic Esophagitis

• APT-1011 is an investigational, once-daily oral disintegrating tablet of fluticasone propionate designed to deliver topical anti-inflammatory effects to the esophagus with minimal systemic exposure. This targeted delivery aims to improve safety versus traditional systemic steroids.
• Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory condition with rising incidence, yet historically had no approved therapies before recent biologic and new oral formulations.
• Regulatory support including Orphan Drug Designation in both the US and Europe and Fast Track designation from the FDA underscore the unmet medical need and potential for expedited approval and review.

2. Strong Clinical Data Supporting Efficacy and Tolerability

• In the Phase III FLUTE-2 study, APT-1011 showed a higher rate of complete symptomatic response (zero dysphagia days) at 12 weeks compared with placebo (27% vs 11%), indicating meaningful clinical benefit.
• APT-1011 also demonstrated improvements in fibrostenotic features (esophageal strictures and grade 2/3 rings), sustained up to 38-52 weeks, suggesting potential disease-modifying effects.
• Ongoing FLUTE-3 Phase III study continues to assess both symptomatic and histologic response over 24 weeks of induction therapy with subsequent long-term safety follow-up.

 

3. Potential Expansion of Treatment Options and Patient Uptake

• APT-1011’s oral disintegrating tablet format may offer convenience and ease of use particularly for pediatric patients compared with existing therapies like subcutaneous biologics or conventional swallowed steroids, potentially supporting broader adoption once approved.
• Improved mucosal adhesion and low systemic absorption are differentiators that may mitigate the systemic side effects often associated with long-term corticosteroid use.

 

4. Market Opportunity and Sales Forecasts in Eosinophilic Esophagitis

• The US EoE market (where APT-1011 is anticipated to launch) is projected to grow from about USD 202 million in 2020 to approximately USD 1.19 billion by 2030, at a CAGR of ~19.4%, driven by shifts from off-label treatments to approved therapies including APT-1011.
• In that forecast, APT-1011 is projected to capture roughly 12.5 % of the US EoE market by 2030, reflecting meaningful but competitive positioning against leading products such as biologic therapy Dupixent and Eohilia.
• Global market forecasts from industry intelligence also suggest the EoE therapy market will continue expanding through 2032 and beyond, although precise APT-1011–specific sales estimates in non-US regions are less widely reported publicly.

 

5. Competitive Positioning and Future Growth Potential

• APT-1011 benefits from multiple regulatory designations that support accelerated development and potential market exclusivity, enhancing its commercial attractiveness.
• Its non-biologic, small-molecule corticosteroid formulation with targeted delivery may appeal to prescribers and patients preferring an oral option over injectables, especially in mild-to-moderate EoE populations where biologics may be seen as overtreatment.
• Continued clinical trial progression (FLUTE-3) and positive outcomes will be key drivers of future regulatory filings, approvals, and uptake.

 

 

APT-1011 Recent Developments

• In May 2024, Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced an oral presentation by Professor Evan Dellon M.D., M.P.H, at the Digestive Disease Week (DDW) 2024 Annual Scientific Meeting. The presentation highlighted encouraging results of APT-1011 (fluticasone propionate orally disintegrating tablet) in the FLUTE-2 Phase III clinical study in Eosinophilic Esophagitis (EoE).

Treatment with APT-1011 in patients with EoE was generally safe and well tolerated. Adverse events were comparable between treatment arms, with the exception of local candidiasis that did not necessitate treatment interruption.  There were no reports of adrenal suppression. 

 

“APT-1011 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of APT-1011 for potential indication like Eosinophilic oesophagitis in the 7MM. A detailed picture of APT-1011’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the APT-1011 for potential indications. The APT-1011 market report provides insights about APT-1011’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current APT-1011 performance, future market assessments inclusive of the APT-1011 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of APT-1011 sales forecasts, along with factors driving its market.

 

APT-1011 Drug Summary

APT-1011 is a novel, once daily, orally disintegrating tablet designed specifically to deliver fluticasone propionate to the esophageal mucosa to exert local anti-inflammatory effects with low systemic absorption. The successful completion of FLUTE 1 (Phase IIb study) and FLUTE-2 (Phase III study) has facilitated the initiation of FLUTE 3. APT-1011 has received Orphan Drug Designation from the FDA and the European Medicines Agency (EMA), and also received Fast Track Designation from the FDA in 2021. This designation was granted based on data evaluating histological remission and symptomatic improvement after 12 weeks (induction) and 52 weeks of treatment. The report provides APT-1011’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the APT-1011 Market Report

The report provides insights into:

• A comprehensive product overview including the APT-1011 MoA, description, dosage and administration, research and development activities in potential indication like Eosinophilic oesophagitis.
• Elaborated details on APT-1011 regulatory milestones and other development activities have been provided in APT-1011 market report.
• The report also highlights APT-1011‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The APT-1011 market report also covers the patents information, generic entry and impact on cost cut.
• The APT-1011 market report contains current and forecasted APT-1011 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The APT-1011 market report also features the SWOT analysis with analyst views for APT-1011 in potential indications.

 

Methodology

The APT-1011 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

APT-1011 Analytical Perspective by DelveInsight

 

In-depth APT-1011 Market Assessment

This APT-1011 sales market forecast report provides a detailed market assessment of APT-1011 for potential indication like Eosinophilic oesophagitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted APT-1011 sales data uptil 2034.

 

APT-1011 Clinical Assessment

The APT-1011 market report provides the clinical trials information of APT-1011 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

APT-1011 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

APT-1011 Market Potential & Revenue Forecast

• Projected market size for the APT-1011 and its key indications
• Estimated APT-1011 sales potential (APT-1011 peak sales forecasts)
• APT-1011 Pricing strategies and reimbursement landscape

 

APT-1011 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• APT-1011 Market positioning compared to existing treatments
• APT-1011 Strengths & weaknesses relative to competitors

 

APT-1011 Regulatory & Commercial Milestones

• APT-1011 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

APT-1011 Clinical Differentiation

• APT-1011 Efficacy & safety advantages over existing drugs
• APT-1011 Unique selling points

 

APT-1011 Market Report Highlights

• In the coming years, the APT-1011 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The APT-1011 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence APT-1011’s dominance.
• Other emerging products for corneal disorders are expected to give tough market competition to APT-1011 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of APT-1011 in potential indications.
• Analyse APT-1011 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted APT-1011 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of APT-1011 in potential indications.

Key Questions Answered In The APT-1011 Market Report: 

• What is the class of therapy, route of administration and mechanism of action of APT-1011? How strong is APT-1011’s clinical and commercial performance?
• What is APT-1011’s clinical trial status in each individual indications such as Eosinophilic oesophagitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the APT-1011 Manufacturers?
• What are the key designations that have been granted to APT-1011 for potential indications? How are they going to impact APT-1011’s penetration in various geographies?
• What is the current and forecasted APT-1011 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of APT-1011 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to APT-1011 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is APT-1011? What is the duration of therapy and what are the geographical variations in cost per patient?